Ítem
Solo Metadatos

The immunotherapy of Guillain-Barré syndrome

Mostrar el registro sencillo de la publicación
dc.creatorRestrepo-Jiménez P.spa
dc.creatorRodríguez Velandia, Yhojan Alexisspa
dc.creatorGonzález P.spa
dc.creatorChang C.spa
dc.creatorGershwin M.E.spa
dc.creatorAnaya, Juan-Manuelspa
dc.date.accessioned2020-05-26T00:07:55Z
dc.date.available2020-05-26T00:07:55Z
dc.date.created2018spa
dc.description.abstractIntroduction: Guillain-Barré syndrome is the most common cause of acute flaccid paralysis worldwide. Microorganisms such as Campylobacter jejuni, Cytomegalovirus, Epstein-Barr virus, Mycoplasma pneumoniae, Haemophilus influenzae and Zika virus have been linked to the disease. The most common clinical variants are acute inflammatory demyelinating polyneuropathy and acute motor axonal neuropathy. Plasma exchange and intravenous immunoglobulins are the standard therapy for the disease. Areas covered: research to elucidate the pathophysiology of Guillain-Barré syndrome has led to the development of drugs directed towards new potential therapeutic targets. This review offers a comprehensive view of the current treatment based upon the physiopathology. Expert opinion: patients with Guillain-Barré syndrome need a multidisciplinary approach, limitation to walk unaided and disability score are indicators for treatment as well as the presence of autonomic dysfunction and pain. Admission to intensive care units should be considered for those patients presenting with respiratory failure, bulbar involvement and progression of the disease. Research aimed to deciphering the pathophysiology of the disease, discovering new biomarkers and establishing algorithms of prediction of both the disease and its outcomes is warranted. © 2018, © 2018 Informa UK Limited, trading as Taylor and Francis Group.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1080/14712598.2018.1468885
dc.identifier.issn14712598
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/24040
dc.language.isoengspa
dc.publisherTaylor and Francis Ltdspa
dc.relation.citationEndPage631
dc.relation.citationIssueNo. 6
dc.relation.citationStartPage619
dc.relation.citationTitleExpert Opinion on Biological Therapy
dc.relation.citationVolumeVol. 18
dc.relation.ispartofExpert Opinion on Biological Therapy, ISSN:14712598, Vol.18, No.6 (2018); pp. 619-631spa
dc.relation.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85048306731&doi=10.1080%2f14712598.2018.1468885&partnerID=40&md5=900b362b595932c9d88fde8e3527217cspa
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.rights.accesoAbierto (Texto Completo)spa
dc.source.instnameinstname:Universidad del Rosariospa
dc.source.reponamereponame:Repositorio Institucional EdocURspa
dc.subject.keywordBisphosphonic acid derivativespa
dc.subject.keywordintravenouseng
dc.subject.keywordBrain derived neurotrophic factorspa
dc.subject.keywordComplementspa
dc.subject.keywordCorticosteroidspa
dc.subject.keywordCoversinspa
dc.subject.keywordCyclophosphamidespa
dc.subject.keywordEculizumabspa
dc.subject.keywordHuman soluble complement receptor type 1spa
dc.subject.keywordImmunoglobulinspa
dc.subject.keywordInterferonspa
dc.subject.keywordMirococeptspa
dc.subject.keywordMycophenolate mofetilspa
dc.subject.keywordNafamstat mesilatespa
dc.subject.keywordProteinspa
dc.subject.keywordRev 576spa
dc.subject.keywordRituximabspa
dc.subject.keywordUnclassified drugspa
dc.subject.keywordImmunologic factorspa
dc.subject.keywordAnalgesiaspa
dc.subject.keywordCerebrospinal fluid filtrationspa
dc.subject.keywordClinical decision makingspa
dc.subject.keywordEmbasespa
dc.subject.keywordGuillain barre syndromespa
dc.subject.keywordHumanspa
dc.subject.keywordImmunotherapyspa
dc.subject.keywordInformation retrievalspa
dc.subject.keywordIntensive care unitspa
dc.subject.keywordMedlinespa
dc.subject.keywordPathophysiologyspa
dc.subject.keywordPharmaceutical carespa
dc.subject.keywordPlasma exchangespa
dc.subject.keywordReviewspa
dc.subject.keywordDisease exacerbationspa
dc.subject.keywordGuillain barre syndromespa
dc.subject.keywordImmunologyspa
dc.subject.keywordImmunotherapyspa
dc.subject.keywordPlasmapheresisspa
dc.subject.keywordProceduresspa
dc.subject.keywordDisease progressionspa
dc.subject.keywordGuillain-barre syndromespa
dc.subject.keywordHumansspa
dc.subject.keywordImmunoglobulinseng
dc.subject.keywordImmunologic factorsspa
dc.subject.keywordImmunotherapyspa
dc.subject.keywordPlasma exchangespa
dc.subject.keywordPlasmapheresisspa
dc.subject.keywordBiological therapyspa
dc.subject.keywordComplementspa
dc.subject.keywordGuillain-barré syndromespa
dc.subject.keywordImmunotherapyspa
dc.subject.keywordIntravenous immunoglobulinsspa
dc.subject.keywordPlasma exchangespa
dc.subject.keywordPolyneuropathyspa
dc.titleThe immunotherapy of Guillain-Barré syndromespa
dc.typearticleeng
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersion
dc.type.spaArtículospa
Archivos
Colecciones
Artículos